recombinant Group B meningococcal vaccine (E. coli)
/ Chongqing Zhifei
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2024
Phase I Clinical Trial of Recombinant Meningococcal Group B Vaccine (E. Coli) in a Population Aged 3 Months-50 Years Old
(clinicaltrials.gov)
- P1 | N=300 | Recruiting | Sponsor: Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
New P1 trial • Infectious Disease • Meningococcal Infections
1 to 1
Of
1
Go to page
1